LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND
32 min
Therapy Area
Drug Classes
Disease Area
All Sessions
Resectable NSCLC
Metastatic NSCLC
SCLC
Biomarkers
Drug Class
Targeted Therapies
Immuno-therapies
Antibody-Drug Conjugates
All
FEATURED
ILCS
Webinars
Articles
From Our Annual Summit
ILCS Sessions
Sep
26
2025
LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND
32 min
Sep
26
2025
Open Discussion on Patient Cases
22 min
Oct
04
2024
Patient Cases & Open Questions
32 min
Oct
04
2024
DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC
33 min
The Reading Room
Articles & Research
Industry Sponsored
Featured Sessions
Sep
26
2025
LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND
32 min
Sep
26
2025
Open Discussion on Patient Cases
22 min
Oct
04
2024
Patient Cases & Open Questions
32 min
Oct
04
2024
DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC
33 min
From Our Annual Summit
ILCS Sessions
Sep
26
2025
LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND
32 min
Sep
26
2025
Open Discussion on Patient Cases
22 min
Oct
04
2024
Patient Cases & Open Questions
32 min
Oct
04
2024
DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC
33 min
The Reading Room